Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Terconazole in vaginal candidiasis. A comparative study].

V Llaca Rodríguez1, H Carrión Tizcareño, P Arguelles Domenzain

  • 1Centro Médico Naval, División de Ginecología y Obstetricia, México, D.F.

Ginecologia Y Obstetricia De Mexico
|November 1, 1990
PubMed
Summary

Terconazole demonstrates high efficacy in treating vaginal candidiasis, achieving significant mycological cure rates. However, partner treatment is crucial to prevent recurrent infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Comparative evaluation of bone mineral density in Mexican women using x-ray bone densitometry and ultrasound].

Ginecologia y obstetricia de Mexico·2000
Same author

[Homage to Dr. Alfredo López de Nava].

Ginecologia y obstetricia de Mexico·1992
Same author

[Terconazol in vaginal candidiasis. Comparative study].

Ginecologia y obstetricia de Mexico·1990
Same author

[Premature labor as a factor in high fetal risk pregnancy].

Ginecologia y obstetricia de Mexico·1979
Same author

[Epidemiological considerations on vaginal candidiasis].

Ginecologia y obstetricia de Mexico·1979
Same author

[Correlation of placentography with estrioluria].

Ginecologia y obstetricia de Mexico·1979

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Vaginal candidiasis is a common fungal infection.
  • Recurrence is a significant challenge in managing vaginal candidiasis.
  • Limited data exists on the long-term efficacy and partner treatment implications for terconazole.

Purpose of the Study:

  • To evaluate the antimycotic action and tolerance of terconazole for vaginal candidiasis.
  • To compare terconazole with clotrimazole in treating vaginal candidiasis.
  • To assess the impact of partner treatment on recurrence rates.

Main Methods:

  • A blind study involving sixty patients with vaginal candidiasis.
  • Three treatment groups: terconazole 240 mg (one dose), terconazole 80 mg (3 days), and clotrimazole 200 mg (3 days).

Related Experiment Videos

  • Mycological and symptomatic evaluations at 10 and 28 days post-treatment; partner treatment varied.

    • Main Results:

    • High initial mycological cure rates at 10 days: 90% (terconazole 240mg), 95% (terconazole 80mg/3 days), 95% (clotrimazole).
    • At 28 days, positive cultures increased: 50% (terconazole 240mg), 40% (terconazole 80mg/3 days), 15% (clotrimazole).
    • Higher recurrence rates in terconazole groups were linked to untreated partners.

    Conclusions:

    • Terconazole shows high clinical and mycological cure rates for vaginal candidiasis.
    • Partner treatment is essential for preventing recidivism in vaginal candidiasis.
    • Terconazole is a viable treatment option, but requires a comprehensive approach including partner management.